Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Increase in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVBGet Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 240,400 shares, an increase of 450.1% from the December 15th total of 43,700 shares. Based on an average daily volume of 2,980,000 shares, the short-interest ratio is presently 0.1 days. Approximately 2.9% of the shares of the company are short sold.

Revelation Biosciences Trading Down 5.5 %

Shares of NASDAQ REVB traded down $0.03 during midday trading on Monday, reaching $0.50. The company had a trading volume of 397,511 shares, compared to its average volume of 16,594,914. The business’s 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.97. Revelation Biosciences has a 1 year low of $0.28 and a 1 year high of $25.26. The stock has a market cap of $2.15 million, a P/E ratio of -0.03 and a beta of 0.24.

About Revelation Biosciences

(Get Free Report)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.

Recommended Stories

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.